SHERLOCK
14 Sep 2023
Trial Summary
Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer
with KRAS G12C mutation
Acronym:
SHERLOCK
ACTRN/NCT /ethics:
ACTRN12622000973718
Scientific title:
Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
Sponsor / Cooperative group:
Amgen Australia Pty Limited
Trial & Patient Characteristics
| Cancer Type | Lung |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-08-31 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | The Queen Elizabeth Hospital |
|---|---|
| Clinical Trial Coordinator | Pamela Cooper |
| Pamela.cooper@sa.gov.au | |
| Phone | 08 8222 6140 |
| Principal Investigator | Rachel Roberts-Thomson |
| Recruitment Status | Recruiting |